[Experimental prevention and suppression of neuroallergic diseases].
For concepts of therapy for neuro-allergic diseases, especially of the encephalomyelitis disseminata type the experimental allergic encephalomyelitis (EAEM)--as a neuro-immunological disease of the first order and a classic pattern for the specification of immunological processes--can be used for more and more extensive testing. After an exposition of the different forms of treatment (prevention, suppression and therapy) and their value the possibility of inducing tolerance a versus the encephalitogenic protein is discussed following the EAEM example--taking the view that all measures taken up to now in the case of neuro-allergic diseases have been unspecific and consequently not set down. In addition emphasis was laid on the assumption of tolerance induction after sensitization which is important to the formation of a therapy for encephalomyelitis disseminata.
D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D007108:Immune Tolerance / Q000187:drug effects; D007165:Immunosuppression Therapy; D011239:Prednisolone / Q000627:therapeutic use; D011817:Rabbits
D011239:Prednisolone
Zur experimentellen Prävention und Suppression neuroallergischer Erkrankungen.